GNLX - Genelux Corporation Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

GNLX

GENELUX CORPORATION

NASDAQ

$2.66

▼ DOWN 7.64% (-0.22)

KEY STATISTICS

Market Cap$119.28 M

52w High$8.54

52w Low$2.29

Dividend Yield—

Frequency—

P/E-3.13

Volume415.35K

Shares Out.44.84M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Thomas D. Zindrick

COMPENSATION 2026

Salary$612,998

Stock Awards$1,420,044

Incentive Plan Pay$168,113

All Other Comp.$3,048

Total$4,277,083

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 26, 2023

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$20.00

Target Low$16.00

Target Median$16.00

Target Consensus$17.33

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.—

NOV

WED

PRICE

$2.66 ▼ DOWN 7.64% (−$0.22)

About Genelux Corporation

https://www.genelux.com ↗

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, including Olvi-Vec for ovarian and lung cancers, V2ACT for pancreatic cancer, and V-VET1 for hematologic and solid cancers.

INDUSTRY

Biotechnology

A PRODUCT GENELUX CORPORATION IS KNOWN FOR

Olvi-Vec (olvimulogene nanivacirepvec)

Olvi-Vec is a proprietary, modified vaccinia virus in Phase 3 clinical trials, developed as a next-generation oncolytic immunotherapy to treat aggressive, hard-to-treat solid tumors, including platinum-resistant ovarian cancer.